Retatrutide vs Mazdutide: What’s the Difference?
The main difference between Retatrutide and Mazdutide is mechanism: Retatrutide is studied for triple-receptor metabolic research — Triple agonist: GLP-1 + GIP + glucagon receptors. Mazdutide is studied for glp-1/glucagon dual agonist weight-loss research — Dual activation of GLP-1 receptors (satiety, insulin) and glucagon receptors (lipolysis, thermogenesis).
Triple agonist vs dual GLP-1/glucagon.
Key differences between Retatrutide and Mazdutide
- •Mechanism: Retatrutide — Triple agonist: GLP-1 + GIP + glucagon receptors. Mazdutide — Dual activation of GLP-1 receptors (satiety, insulin) and glucagon receptors (lipolysis, thermogenesis).
- •Primary research focus: Retatrutide is studied for triple-receptor metabolic research; Mazdutide is studied for glp-1/glucagon dual agonist weight-loss research.
- •Overlap: the two compounds share weight loss & metabolism.
- •Discussion context: Retatrutide is most often discussed alongside triple-receptor metabolic research, while Mazdutide centres on glp-1/glucagon dual agonist weight-loss research.
| Attribute | Retatrutide Triple agonist (GLP-1/GIP/Glucagon) | Mazdutide IBI362, GLP-1/Glucagon dual agonist |
|---|---|---|
| Category | Weight Loss & Metabolism | Weight Loss & Metabolism |
| Best known for | Triple-receptor metabolic research | GLP-1/glucagon dual agonist weight-loss research |
| Mechanism of action | Triple agonist: GLP-1 + GIP + glucagon receptors. Glucagon arm uniquely increases caloric expenditure on top of appetite suppression. | Dual activation of GLP-1 receptors (satiety, insulin) and glucagon receptors (lipolysis, thermogenesis). |
| Human research | Moderate | Not catalogued |
| Animal research | Strong | Not catalogued |
| Mechanistic research | Established | Not catalogued |
| Study cadence cited | Once weekly, subcutaneous | — |
| In plain English | Retatrutide pulls three levers — appetite, insulin response, and energy expenditure via glucagon. Trials have shown the largest weight reductions of any incretin to date. | GLP-1 reduces appetite; glucagon raises energy expenditure. Together they aim for more weight loss than GLP-1 alone. |
| How it works | GLP-1 reduces appetite. GIP enhances insulin response. Glucagon receptor activation increases energy expenditure and fat oxidation. | Dual activation of GLP-1 receptors (satiety, insulin) and glucagon receptors (lipolysis, thermogenesis). |
| Researchers study | Obesity, hepatic steatosis, and metabolic syndrome. | Obesity and metabolic-associated liver disease, particularly in Chinese clinical research. |
| Internet discussion | Treated as the 'next big thing' in metabolic forums. Discussion centers on side effect profile vs Tirzepatide. | Discussed alongside survodutide and Retatrutide in next-gen metabolic research. |
Mechanism and research evidence, side by side
How Retatrutide and Mazdutide differ at the receptor level, and how much published research currently supports each. Evidence ratings describe the depth of publicly available literature — they are not claims of safety or effectiveness.
Retatrutide
Triple agonist: GLP-1 + GIP + glucagon receptors. Glucagon arm uniquely increases caloric expenditure on top of appetite suppression.
- Incretin and appetite-regulating receptors
- Slowed gastric emptying and altered satiety signalling
- Energy-balance and glycaemic research endpoints
- Human research
- Moderate
- Animal research
- Strong
- Mechanistic research
- Established
Rapid weight loss (trials show ~24% body weight loss — highest of any compound in this class to date)
Retatrutide
Triple-receptor metabolic research
Retatrutide pulls three levers — appetite, insulin response, and energy expenditure via glucagon. Trials have shown the largest weight reductions of any incretin to date.
GLP-1 reduces appetite. GIP enhances insulin response. Glucagon receptor activation increases energy expenditure and fat oxidation.
Obesity, hepatic steatosis, and metabolic syndrome.
Treated as the 'next big thing' in metabolic forums. Discussion centers on side effect profile vs Tirzepatide.
Retatrutide is an investigational triple agonist showing the largest weight-loss signals in metabolic research to date.
Mazdutide
GLP-1/glucagon dual agonist weight-loss research
GLP-1 reduces appetite; glucagon raises energy expenditure. Together they aim for more weight loss than GLP-1 alone.
Dual activation of GLP-1 receptors (satiety, insulin) and glucagon receptors (lipolysis, thermogenesis).
Obesity and metabolic-associated liver disease, particularly in Chinese clinical research.
Discussed alongside survodutide and Retatrutide in next-gen metabolic research.
Mazdutide is a GLP-1/glucagon dual agonist researched for obesity and metabolic disease.